What’s next for Merck?

Another huge deal in the pharmaceutical industry. Merck finalized the sale of its consumer health division today to Germany’s Bayer, selling off popular brand names like Claritin, Coppertone and Dr. Scholl’s foot care products. Despite that $14 billion sale, shares of Merck were the biggest decliners in the Dow today, falling 2.5 percent. Meg Tirrell was at Merck’s analyst day in Boston, where she spoke with the drug maker’s CEO about this latest deal and what’s next for the company.

This entry was posted in Biotech & Pharmaceuticals, M&A, NBR Show Clips. Bookmark the permalink.

Leave a Reply